CS390691A3 - Olefinic 1h-imidazo-(4,5-c)quinolin-4-amines - Google Patents

Olefinic 1h-imidazo-(4,5-c)quinolin-4-amines Download PDF

Info

Publication number
CS390691A3
CS390691A3 CS913906A CS390691A CS390691A3 CS 390691 A3 CS390691 A3 CS 390691A3 CS 913906 A CS913906 A CS 913906A CS 390691 A CS390691 A CS 390691A CS 390691 A3 CS390691 A3 CS 390691A3
Authority
CS
Czechoslovakia
Prior art keywords
carbon atoms
straight
group
branched chain
phenyl
Prior art date
Application number
CS913906A
Other languages
Czech (cs)
English (en)
Inventor
John F Gerster
Roy T Knafla
Original Assignee
Minnesota Mining & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg
Publication of CS390691A3 publication Critical patent/CS390691A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CS913906A 1989-03-23 1991-12-19 Olefinic 1h-imidazo-(4,5-c)quinolin-4-amines CS390691A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/327,693 US4929624A (en) 1989-03-23 1989-03-23 Olefinic 1H-imidazo(4,5-c)quinolin-4-amines

Publications (1)

Publication Number Publication Date
CS390691A3 true CS390691A3 (en) 1992-06-17

Family

ID=23277629

Family Applications (1)

Application Number Title Priority Date Filing Date
CS913906A CS390691A3 (en) 1989-03-23 1991-12-19 Olefinic 1h-imidazo-(4,5-c)quinolin-4-amines

Country Status (9)

Country Link
US (1) US4929624A (ja)
EP (1) EP0389302B1 (ja)
JP (1) JP2942584B2 (ja)
KR (1) KR0180226B1 (ja)
AU (1) AU632099B2 (ja)
CA (1) CA2012226C (ja)
CS (1) CS390691A3 (ja)
DE (1) DE69011914T2 (ja)
ES (1) ES2060026T3 (ja)

Families Citing this family (272)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756747A (en) * 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
ES2094141T3 (es) * 1989-02-27 1997-01-16 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolin-4-aminas como antivirales.
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
ATE121088T1 (de) * 1990-10-05 1995-04-15 Minnesota Mining & Mfg Verfahren zur herstellung von imidazo(4,5- c>chinolin-4-aminen.
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US6608201B2 (en) 1992-08-28 2003-08-19 3M Innovative Properties Company Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
EP0708772B1 (en) * 1993-07-15 2000-08-23 Minnesota Mining And Manufacturing Company IMIDAZO [4,5-c]PYRIDIN-4-AMINES
US5648516A (en) * 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5644063A (en) * 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
KR100518903B1 (ko) 1996-10-25 2005-10-06 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 Ｔｈ2 매개 질병 및 관련 질병의 치료용 면역 반응 조절 화합물
US6069149A (en) * 1997-01-09 2000-05-30 Terumo Kabushiki Kaisha Amide derivatives and intermediates for the synthesis thereof
AU2002300985B2 (en) * 1997-12-11 2004-12-02 Minnesota Mining And Manufacturing Company Imidazonaphthyridines And Their Use In Inducing Cytokine Biosynthesis
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
DK1512685T3 (da) * 1997-12-11 2006-11-20 Minnesota Mining & Mfg Imidazonaphthyridiner og deres anvendelse til induktion af cytokinbiosyntese
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6518280B2 (en) * 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
NZ512628A (en) 1999-01-08 2004-03-26 3M Innovative Properties Co Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
JP3436512B2 (ja) * 1999-12-28 2003-08-11 株式会社デンソー アクセル装置
US6894060B2 (en) * 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
UA74593C2 (en) * 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
CA2598144A1 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
WO2002046749A2 (en) * 2000-12-08 2002-06-13 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
JP2005501550A (ja) * 2001-08-30 2005-01-20 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調整剤分子を用いた形質細胞様樹状細胞を成熟させる方法
EP1478371A4 (en) * 2001-10-12 2007-11-07 Univ Iowa Res Found METHODS AND PRODUCTS FOR ENHANCING IMMUNE RESPONSES USING IMIDAZOQUINOLINE COMPOUND
JP2005513021A (ja) * 2001-11-16 2005-05-12 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトール様受容体経路に関する方法および組成物
MXPA04005023A (es) * 2001-11-29 2004-08-11 3M Innovative Properties Co Formulaciones farmaceuticas que comprenden un modificador de respuesta inmune.
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
NZ534566A (en) * 2002-02-22 2007-02-23 3M Innovative Properties Co Method of reducing and treating UVB-induced immunosuppression
WO2003080112A2 (en) * 2002-03-19 2003-10-02 Powdermed Limited Imidazoquinolineamines as adjuvants in hiv dna vaccination
AU2003216851B2 (en) * 2002-03-19 2008-04-17 Powderject Research Limited Imidazoquinoline adjuvants for vaccines
NZ573064A (en) * 2002-04-04 2011-02-25 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
US6743920B2 (en) 2002-05-29 2004-06-01 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
NZ537054A (en) * 2002-06-07 2006-10-27 3M Innovative Properties Co Ether substituted imidazopyridines
EP2269632B1 (en) 2002-08-15 2014-01-01 3M Innovative Properties Co. Immunostimulatory compositions and methods of stimulating an immune response
JP2006503068A (ja) * 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー １ｈ−イミダゾダイマー
WO2004053452A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Assays relating to toll-like receptor activity
WO2004053057A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
WO2004058759A1 (en) * 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
JP2006512391A (ja) 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー 組み合わせ免疫賦活薬
US7375180B2 (en) * 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
WO2004075865A2 (en) * 2003-02-27 2004-09-10 3M Innovative Properties Company Selective modulation of tlr-mediated biological activity
AU2004218349A1 (en) 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
JP2006519877A (ja) * 2003-03-07 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー １−アミノ１ｈ−イミダゾキノリン
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
CA2518445A1 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
CA2518082C (en) * 2003-03-13 2013-02-12 3M Innovative Properties Company Methods for diagnosing skin lesions
CN100558361C (zh) * 2003-03-13 2009-11-11 3M创新有限公司 改善皮肤质量的方法
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
AU2004244962A1 (en) * 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
WO2004110992A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company Process for imidazo[4,5-c] pyridin-4-amines
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
AU2004261243A1 (en) * 2003-07-31 2005-02-10 3M Innovative Properties Company Bioactive compositions comprising triazines
CA2534313C (en) * 2003-08-05 2013-03-19 3M Innovative Properties Company Formulations containing an immune response modifier
MXPA06001669A (es) 2003-08-12 2006-04-28 3M Innovative Properties Co Compuestos que contienen imidazo-oxima sustituidos.
CA2535338C (en) * 2003-08-14 2013-05-28 3M Innovative Properties Company Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
US8961477B2 (en) * 2003-08-25 2015-02-24 3M Innovative Properties Company Delivery of immune response modifier compounds
US20050048072A1 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
US7897597B2 (en) 2003-08-27 2011-03-01 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
CA2536578A1 (en) * 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
WO2005023190A2 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
JP2007505629A (ja) * 2003-09-17 2007-03-15 スリーエム イノベイティブ プロパティズ カンパニー Ｔｌｒ遺伝子発現の選択的調節
WO2005033049A2 (en) * 2003-10-01 2005-04-14 Taro Pharmaceuticals U.S.A., Inc. METHOD OF PREPARING 4-AMINO-1H-IMIDAZO(4,5-c)QUINOLINES AND ACID ADDITION SALTS THEREOF
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
CA2540598C (en) 2003-10-03 2013-09-24 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US20050096259A1 (en) * 2003-10-31 2005-05-05 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
CA2545774A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
ES2308272T3 (es) * 2003-11-21 2008-12-01 Novartis Ag Derivados de 1h-imidazoquinolina como inhibidores de la proteina quinasa.
AU2004293078B2 (en) * 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2005051324A2 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8940755B2 (en) * 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
AU2004315771A1 (en) * 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
CA2552101A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
EP1701955A1 (en) 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
CA2551399A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
WO2005067500A2 (en) * 2003-12-30 2005-07-28 3M Innovative Properties Company Enhancement of immune responses
EP1729768B1 (en) 2004-03-15 2018-01-10 Meda AB Immune response modifier formulations and methods
EP1730143A2 (en) 2004-03-24 2006-12-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
JP2007532572A (ja) * 2004-04-09 2007-11-15 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調整剤を送達させるための方法、組成物および調製物
CN101426524A (zh) * 2004-04-28 2009-05-06 3M创新有限公司 用于粘膜接种疫苗的组合物和方法
EP1766034B1 (en) 2004-05-21 2014-03-19 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for influenza virus vaccines
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
WO2005123079A2 (en) * 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US7884207B2 (en) * 2004-06-18 2011-02-08 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
ITMI20041282A1 (it) * 2004-06-24 2004-09-24 Dipharma Spa Procedimento per la preparazione di imiquimod
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
WO2006026470A2 (en) * 2004-08-27 2006-03-09 3M Innovative Properties Company Hiv immunostimulatory compositions
CA2578741C (en) * 2004-09-02 2014-01-14 3M Innovative Properties Company 1-alkoxy 1h-imidazo ring systems and methods
EP1784180A4 (en) 2004-09-02 2009-07-22 3M Innovative Properties Co 2-AMINO-1H-IMIDAZO RING SYSTEMS AND METHOD
EP1804583A4 (en) * 2004-10-08 2009-05-20 3M Innovative Properties Co ADJUVANT FOR DNA VACCINE
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
AU2005322898B2 (en) 2004-12-30 2011-11-24 3M Innovative Properties Company Chiral fused (1,2)imidazo(4,5-c) ring compounds
EP1830876B1 (en) 2004-12-30 2015-04-08 Meda AB Use of imiquimod for the treatment of cutaneous metastases derived from a breast cancer tumor
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
JP2008526751A (ja) * 2004-12-30 2008-07-24 武田薬品工業株式会社 １−（２−メチルプロピル）−１ｈ−イミダゾ［４，５−ｃ］［１，５］ナフチリジン−４−アミンエタンスルホナート及び１−（２−メチルプロピル）−１ｈ−イミダゾ［４，５−ｃ］［１，５］ナフチリジン−４−アミンメタンスルホナート
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
JP2008530252A (ja) 2005-02-09 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド オキシムおよびヒドロキシルアミンで置換されたチアゾロ［４，５−ｃ］環化合物ならびに方法
CA2597324C (en) 2005-02-09 2015-06-30 Coley Pharmaceutical Group, Inc. Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
JP2008530113A (ja) 2005-02-11 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド オキシムおよびヒドロキシラミン置換イミダゾ［４，５−ｃ］環化合物および方法
EP1845988A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
EP1858919B1 (en) 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
EP1858920B1 (en) 2005-02-18 2016-02-03 GlaxoSmithKline Biologicals SA Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
AU2006223634A1 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
JP2008538203A (ja) 2005-02-23 2008-10-16 コーリー ファーマシューティカル グループ，インコーポレイテッド インターフェロンの生合成を優先的に誘導する方法
JP2008531567A (ja) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン化合物および方法
EP1851220A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazonaphthyridines
CN101175493A (zh) * 2005-03-14 2008-05-07 3M创新有限公司 治疗光化性角化病的方法
AU2006232377A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
WO2006107851A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2008539252A (ja) * 2005-04-25 2008-11-13 スリーエム イノベイティブ プロパティズ カンパニー 免疫活性化組成物
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007011777A2 (en) 2005-07-18 2007-01-25 Novartis Ag Small animal model for hcv replication
ES2577514T3 (es) * 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8476292B2 (en) 2005-09-09 2013-07-02 3M Innovative Properties Company Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
US7629027B2 (en) * 2005-10-14 2009-12-08 3M Innovative Properties Company Method for making chromonic nanoparticles
US7718716B2 (en) * 2005-10-14 2010-05-18 3M Innovative Properties Company Chromonic nanoparticles containing bioactive compounds
WO2007047749A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Mucosal and systemic immunizations with alphavirus replicon particles
US20070100146A1 (en) * 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
EP2368572B1 (en) 2005-11-04 2020-03-04 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP1948173B1 (en) 2005-11-04 2013-07-17 3M Innovative Properties Company Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
JP2009514850A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
US20070128291A1 (en) * 2005-12-07 2007-06-07 Tokie Jeffrey H Method and Apparatus for Forming Chromonic Nanoparticles
US7807661B2 (en) * 2005-12-08 2010-10-05 3M Innovative Properties Company Silver ion releasing articles and methods of manufacture
US7323568B2 (en) * 2005-12-12 2008-01-29 Chemagis Ltd. Process for preparing Imiquimod
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR20110110853A (ko) 2006-01-27 2011-10-07 노파르티스 파르마 아게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US8951528B2 (en) * 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
ES2388556T3 (es) * 2006-03-23 2012-10-16 Novartis Ag Compuestos inmunopotenciadores
US20100010217A1 (en) * 2006-03-23 2010-01-14 Valiante Nicholas M Methods for the preparation of imidazole-containing compounds
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
US20100068223A1 (en) 2006-03-24 2010-03-18 Hanno Scheffczik Storage of Influenza Vaccines Without Refrigeration
CA2647942A1 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
US20070275185A1 (en) * 2006-05-23 2007-11-29 3M Innovative Properties Company Method of making ordered nanostructured layers
CA2653941C (en) 2006-05-31 2013-01-08 The Regents Of The University Of California Substituted amino purine derivatives and uses thereof
EP2054431B1 (en) 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
US20100129403A1 (en) 2006-06-20 2010-05-27 Transgene S.A. Recombinant viral vaccine
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
WO2008030511A2 (en) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
CN106045993A (zh) * 2006-11-20 2016-10-26 诺华股份有限公司 化合物的盐和晶型
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US7943771B2 (en) * 2007-01-24 2011-05-17 Chemagis Ltd. Imiquimod production process
SI2510946T1 (sl) 2007-02-07 2015-12-31 The Regents Of The University Of California Konjugati sintetičnih agonistov TLR in njihove uporabe
US7659398B2 (en) * 2007-02-14 2010-02-09 Chemagis Ltd. Imiquimod production process
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
AU2008299376B2 (en) 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2008340053A1 (en) 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as PI 3 kinase inhibitors
BRPI0821240B8 (pt) 2007-12-21 2022-10-04 Novartis Ag formas mutantes de estreptolisina o
EA201001264A1 (ru) * 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
EP2268309B1 (en) 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
US20100160368A1 (en) * 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
MX2011008500A (es) * 2009-02-11 2011-09-26 Univ California Moduladores del receptor tipo toll y tratamiento de enfermedades.
JP2012519482A (ja) 2009-03-06 2012-08-30 ノバルティス アーゲー クラミジア抗原
CN103800906B (zh) 2009-03-25 2017-09-22 德克萨斯大学系统董事会 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
US8679505B2 (en) 2009-04-14 2014-03-25 Novartis Ag Compositions for immunising against Staphylococcus aureus
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
US8629151B2 (en) 2009-05-27 2014-01-14 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AU2010274097B2 (en) 2009-07-13 2016-06-16 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
JP2012532626A (ja) 2009-07-16 2012-12-20 ノバルティス アーゲー 無毒化されたＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US9597326B2 (en) 2010-04-13 2017-03-21 Glaxosmithkline Biologicals Sa Benzonapthyridine compositions and uses thereof
EP2575773A4 (en) 2010-05-26 2014-06-25 Selecta Biosciences Inc SYNTHETIC NANOTRÄGERKOMBINATIONSIMPFSTOFFE
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
EP3222621B1 (en) 2010-08-17 2023-03-08 3M Innovative Properties Company Lipidated immune response modifier compound and its medical use
PT2667892T (pt) 2011-01-26 2019-06-07 Glaxosmithkline Biologicals Sa Regime de imunização contra o vsr
AU2012213080B2 (en) 2011-01-31 2014-03-27 Novartis Ag Novel heterocyclic derivatives
JP2014519819A (ja) 2011-05-13 2014-08-21 ノバルティス アーゲー 融合前ｒｓｖｆ抗原
JP6415979B2 (ja) 2011-06-03 2018-10-31 スリーエム イノベイティブ プロパティズ カンパニー ヒドラジノ１ｈ−イミダゾキノリン−４−アミン及びこれから調製された複合体
MX347240B (es) 2011-06-03 2017-04-20 3M Innovative Properties Co Ligadores heterobifuncionales con segmentos polietilenglicol y conjugados modificadores de la respuesta inmunitaria elaborados a partir de los mismos.
EP3508219A1 (en) 2011-07-06 2019-07-10 GlaxoSmithKline Biologicals S.A. Self-replicating rna prime - protein boost vaccines
ES2656050T3 (es) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Composiciones de combinación inmunogénica y usos de las mismas
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
CN103702687A (zh) 2011-07-29 2014-04-02 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
WO2013061305A1 (en) 2011-10-28 2013-05-02 Novartis Ag Novel purine derivatives and their use in the treatment of disease
US9493517B2 (en) 2011-11-07 2016-11-15 Glaxosmithkline Biologicals Sa Conjugates comprising an antigen and a carrier molecule
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
CN105457021A (zh) 2012-05-04 2016-04-06 辉瑞公司 前列腺相关抗原及基于疫苗的免疫治疗疗法
EP2849756A1 (en) 2012-05-16 2015-03-25 Novartis AG Dosage regimen for a pi-3 kinase inhibitor
EP2869842A1 (en) 2012-07-06 2015-05-13 Novartis AG Immunogenic compositions and uses thereof
WO2014107663A2 (en) 2013-01-07 2014-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous t cell lymphoma
US9919029B2 (en) 2013-07-26 2018-03-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
SG10201803802YA (en) 2013-11-05 2018-06-28 3M Innovative Properties Co Sesame oil based injection formulations
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
KR20160095035A (ko) 2013-12-06 2016-08-10 노파르티스 아게 알파-이소형 선택성 포스파티딜이노시톨 3-키나제 억제제를 위한 투여 요법
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
US10421971B2 (en) 2014-01-15 2019-09-24 The University Of Chicago Anti-tumor therapy
JP6894237B2 (ja) 2014-03-26 2021-06-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 変異体ブドウ球菌抗原
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
US10526309B2 (en) 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors
JP2018532750A (ja) 2015-11-02 2018-11-08 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
IL266562B1 (en) 2016-11-09 2024-07-01 Univ Texas Pharmaceutical compositions for immune regulation adapted for use in the patient sensitive to allergen-induced asthma
CN111511740B (zh) 2017-12-20 2023-05-16 3M创新有限公司 用作免疫应答调节剂的带有支链连接基团的酰胺取代的咪唑并[4,5-c]喹啉化合物
CN109970572B (zh) * 2017-12-22 2022-04-22 万华化学集团股份有限公司 一种双键封端化合物的合成方法
US11059876B2 (en) 2018-02-28 2021-07-13 Pfizer Inc. IL-15 variants and uses thereof
JP7384835B2 (ja) 2018-05-23 2023-11-21 ファイザー・インク Ｃｄ３に特異的な抗体及びその使用
MX2020012607A (es) 2018-05-23 2021-01-29 Pfizer Anticuerpos especificos para gucy2c y sus usos.
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2021116420A1 (en) 2019-12-13 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
CA3164623A1 (en) 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
AU2021308586A1 (en) 2020-07-17 2023-03-02 Pfizer Inc. Therapeutic antibodies and their uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700674A (en) 1969-04-30 1972-10-24 American Cyanamid Co 4-alkylamino-3-nitroquinolines
DE3204126A1 (de) * 1982-02-06 1983-08-11 Bayer Ag, 5090 Leverkusen Pyrazoloxazine, -thiazine, -chinoline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4563525A (en) * 1983-05-31 1986-01-07 Ici Americas Inc. Process for preparing pyrazolopyridine compounds
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
CA1271477A (en) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
ZA848968B (en) * 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
US4698346A (en) * 1985-05-08 1987-10-06 Usv Pharmaceutical Corporation Thiazolo[5,4-h]quinoline compounds useful as anti-allergy agents
DD242806A1 (de) 1985-11-20 1987-02-11 Univ Dresden Tech Verfahren zur herstellung von 3,4-diamino-chinolin-2-onen
ES2094141T3 (es) * 1989-02-27 1997-01-16 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolin-4-aminas como antivirales.

Also Published As

Publication number Publication date
KR900014381A (ko) 1990-10-23
CA2012226A1 (en) 1990-09-23
JPH0327381A (ja) 1991-02-05
CA2012226C (en) 2000-05-30
EP0389302B1 (en) 1994-08-31
ES2060026T3 (es) 1994-11-16
DE69011914D1 (de) 1994-10-06
DE69011914T2 (de) 1995-03-23
KR0180226B1 (ko) 1999-03-20
JP2942584B2 (ja) 1999-08-30
AU5142690A (en) 1990-09-27
AU632099B2 (en) 1992-12-17
EP0389302A1 (en) 1990-09-26
US4929624A (en) 1990-05-29

Similar Documents

Publication Publication Date Title
CS390691A3 (en) Olefinic 1h-imidazo-(4,5-c)quinolin-4-amines
US4689338A (en) 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
US5525612A (en) 1-substituted 1H-imidazo-[4,5-c]quinolin-4-amines
EP0145340B1 (en) 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines
US5648516A (en) Fused cycloalkylimidazopyridines
US5037986A (en) Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US5352784A (en) Fused cycloalkylimidazopyridines
US5446153A (en) Intermediates for imidazo[4,5-c]pyridin-4-amines
US5644063A (en) Imidazo[4,5-c]pyridin-4-amine intermediates
US5605899A (en) 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
CZ285050B6 (cs) 1-Substituované, 2-substituované-1H-imidazo/4,5-c /chinolin-4-aminy
JPH0327380A (ja) １ｈ―イミダゾ〔４，５―ｃ〕キノリン―４―アミン類
IE51542B1 (en) Therapeutic agents
JP2651912B2 (ja) イミダゾール誘導体、それらの製造法及び薬剤としての使用
EP0287971B1 (en) Benzimidazole derivatives and process for their preparations
DK164787B (da) 3-substituerede pyrazolooe1,5-aaapyridinderivater, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
JPS6160832B2 (ja)
HU184968B (en) Process for preparing quinolone derivatives
CS344191A3 (en) Novel isoquinoline derivatives, process of their preparation and pharmaceuticals comprising them
YAGINUMA It was previously reported that 4-chloro-5-(2-hydroxyethylamino)-3 (2H)-pyridazinones
JPS633859B2 (ja)
CS244698B2 (cs) Způsob výroby v poloze 9 substituovaných derivátů 4-oxo-4H- -pyrido[1,2-a]-pyrimidinu

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic